Patrick Archdeacon, MD, MPhil
Medical Officer, US Food and Drug Administration
Patrick Archdeacon, MD, MPhil, is a medical officer in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). His work at the Office of Medical Policy has included involvement in the Clinical Trials Transformation Initiative (a public-private partnership that identifies practices to increase the quality and efficiency of clinical trials) and the Sentinel Initiative (a system that will draw on existing automated healthcare data from multiple sources to actively monitor the safety of medical products continuously and in real time). In addition, he serves as the FDA co-chair of the Kidney Health Initiative (a public-private partnership founded by FDA and the American Society of Nephrology). He attended medical school at Columbia University’s School of Physicians and Surgeons. Prior to joining FDA, he completed his training in internal medicine at the New York Presbyterian Hospital and in nephrology and transplant nephrology at the University of North Carolina.
Archdeacon served as a member of the Advisory Panel on Clinical Trials from August 2016 to August 2019.
Conflicts of Interest
As of March 31, 2016
- US Food and Drug Administration, Employee
- FDA Co-Chair of the Kidney Health Initiative’s Board of Directors
- Clinical Trials Transformation Initiative, on the Steering Committee
- Advisory Panel Member